Predict your next investment

HEALTHCARE | Drug Development
renatherapeutics.com

See what CB Insights has to offer

Stage

Acquired | Acquired

About Rena Therapeutics

Rena Therapeutics is a venture company authorized by Tokyo Medical and Dental University (TMDU) in order to accelerate the Hetero Duplex Oligonucleotide (HDO) technology and drive commercialization of oligonucleotide drug. The HDO technology is invented by Professor Takanori Yokota of TMDU, Professor Satoshi Obika of Osaka University and others.On November 22, 2019, Rena Therapeutics was acquired by Nippon Shokubai. The terms of the agreement were not disclosed.

Rena Therapeutics Headquarter Location

Office:Otemachi Financial City Grand Cube 3F

Tokyo, 1-9-2,

Japan

Latest Rena Therapeutics News

Nippon Shokubai : Acquires the Ownership of Rena Therapeutics

Nov 22, 2019

0 Message : Nov. 22, 2019 OSAKA, JAPAN, November 22, 2019 - NIPPON SHOKUBAI CO., LTD. (Headquarter: Osaka, Chuo-ku, hereinafter 'Nippon Shokubai') announces that it has purchased issued and outstanding shares of Rena Therapeutics Inc. (Headquarter: Tokyo, Chiyoda-ku, hereinafter 'Rena Therapeutics') and acquired the ownership of Rena Therapeutics in November 21st, 2019. 1. About Rena Therapeutics Rena Therapeutics is a venture company authorized by Tokyo Medical and Dental University (TMDU) in order to accelerate the Hetero Duplex Oligonucleotide (HDO) technology and drive commercialization of oligonucleotide drug. The HDO technology is invented by Professor Takanori Yokota of TMDU, Professor Satoshi Obika of Osaka University and others. Oligonucleotide drug has been expected as new modality for treating intractable diseases, however, issues such as instability in blood and side effects have been revealed and widely recognized. HDO is composed of double stranded DNA/RNA with ligand molecules for proper drug delivery (Figure1), and it is strongly expected to overcome these issues. Evaluated the high possibility of HDO technology, Rena Therapeutics executed non-exclusive license agreements with Ionis Pharmaceuticals, Inc. which is global leading company in RNA-targeted drug discovery and development, and Takeda Pharmaceutical Company Limited. which is the largest Pharmaceutical company in Japan. Nippon Shokubai invested in Rena Therapeutics to support its R&D and promote relationship in June 2017. 2. Purpose of transaction Nippon Shokubai is establishing the Health and Medical Business, focusing on the fields of oligonucleotide drug, peptide drug, and Drug Delivery System (DDS). Nippon Shokubai plans to develop the DDS technology of oligonucleotide drug through this acquisition. By means of not only active business support from Nippon Shokubai to Rena Therapeutics but also the cooperation with Rena Therapeutics, TMDU, and Osaka University, Nippon Shokubai will promote HDO technology to be practical. Nippon Shokubai tries to expand the contracted API manufacturing business acquiring new clients such as pharmaceutical companies as a result of manufacturing HDO structured API. 3. Overview of transaction

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Rena Therapeutics Patents

Rena Therapeutics has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/19/2009

5/31/2016

Water pollution, Water treatment, Environmental engineering, Robotics, Proteins

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/19/2009

00/00/0000

Grant Date

5/31/2016

00/00/0000

Title

Subscribe to see more

Related Topics

Water pollution, Water treatment, Environmental engineering, Robotics, Proteins

Subscribe to see more

Status

Grant

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.